Acquisitions11 Nov 2026, 06:30 pm
Alivus Life Sciences Acquires 65.01% Stake in IQGEN-X Pharma
AI Summary
Alivus Life Sciences Ltd has initiated the closing process for its acquisition of a 76% stake in IQGEN-X Pharma Private Limited. The company has successfully acquired 7,36,096 equity shares, representing 65.01% of IQGEN-X's issued and paid-up equity share capital. The remaining shares will be acquired in due course. Consequently, IQGEN-X Pharma Private Limited has officially become a subsidiary of Alivus Life Sciences Ltd, effective from today. This strategic move is expected to bolster Alivus Life Sciences' presence in the pharmaceutical sector.
Key Highlights
- Alivus Life Sciences acquires majority stake in IQGEN-X Pharma.
- 65.01% stake acquired, with remaining shares to follow.
- IQGEN-X Pharma is now a subsidiary of Alivus Life Sciences.
- Acquisition marks a significant step for the company's growth.
Price Impact
More from ALIVUS